SU1442077A3 - Способ получени замещенных андроста-1,4-диен-3,17-дионов - Google Patents
Способ получени замещенных андроста-1,4-диен-3,17-дионов Download PDFInfo
- Publication number
- SU1442077A3 SU1442077A3 SU864027793A SU4027793A SU1442077A3 SU 1442077 A3 SU1442077 A3 SU 1442077A3 SU 864027793 A SU864027793 A SU 864027793A SU 4027793 A SU4027793 A SU 4027793A SU 1442077 A3 SU1442077 A3 SU 1442077A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- dione
- aromatase
- diene
- compound
- vivo
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- LUJVUUWNAPIQQI-QAGGRKNESA-N androsta-1,4-diene-3,17-dione Chemical class O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 LUJVUUWNAPIQQI-QAGGRKNESA-N 0.000 title claims description 3
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical class O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 claims abstract description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229940088597 hormone Drugs 0.000 claims abstract description 3
- 239000005556 hormone Substances 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 25
- 102000014654 Aromatase Human genes 0.000 claims description 11
- 108010078554 Aromatase Proteins 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000011534 incubation Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 241000700159 Rattus Species 0.000 claims description 4
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 4
- 239000003886 aromatase inhibitor Substances 0.000 claims description 3
- 229940046844 aromatase inhibitors Drugs 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000003228 microsomal effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- GIKNHHRFLCDOEU-UHFFFAOYSA-N 4-(2-aminopropyl)phenol Chemical compound CC(N)CC1=CC=C(O)C=C1 GIKNHHRFLCDOEU-UHFFFAOYSA-N 0.000 claims description 2
- 230000007059 acute toxicity Effects 0.000 claims description 2
- 231100000403 acute toxicity Toxicity 0.000 claims description 2
- 229960005471 androstenedione Drugs 0.000 claims description 2
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000006356 dehydrogenation reaction Methods 0.000 claims 2
- 239000003960 organic solvent Substances 0.000 claims 2
- 229960005353 testolactone Drugs 0.000 claims 2
- LUJVUUWNAPIQQI-UHFFFAOYSA-N (+)-androsta-1,4-diene-3,17-dione Natural products O=C1C=CC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 LUJVUUWNAPIQQI-UHFFFAOYSA-N 0.000 claims 1
- 101100238516 Rattus norvegicus Mrgprx1 gene Proteins 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960001957 stomatological preparations Drugs 0.000 claims 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- KQRGETZTRARSMA-DAELLWKTSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-6-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 KQRGETZTRARSMA-DAELLWKTSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- NNGITUHFLCZEKQ-UHFFFAOYSA-N 2,4-dichloro-3,6-dioxocyclohexa-1,4-diene-1-carbonitrile Chemical compound ClC1=CC(=O)C(C#N)=C(Cl)C1=O NNGITUHFLCZEKQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- OISXSKBKUGOOCH-JBDAPHQKSA-N (8S,9S,10R,13S,14S)-4,10,13-trimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene Chemical compound CC1=C2CC[C@@H]3[C@H](CC[C@@]4(CCC[C@H]43)C)[C@]2(CCC1)C OISXSKBKUGOOCH-JBDAPHQKSA-N 0.000 description 1
- SXCIYMOQZBTPSL-LPBINRMYSA-N (8S,9S,10S,13S,14S)-9,10,13-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C[C@@]12[C@]3(CCC(C=C3CC[C@H]1[C@@H]1CCC([C@@]1(C)CC2)=O)=O)C SXCIYMOQZBTPSL-LPBINRMYSA-N 0.000 description 1
- YGAJSUBVNAASGG-ORZNMBHWSA-N (8r,9s,10r,13r,14s)-13-ethenyl-10-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@]1(C(=O)CC[C@H]1[C@@H]1CC2)C=C)C[C@@H]1[C@]1(C)C2=CC(=O)C=C1 YGAJSUBVNAASGG-ORZNMBHWSA-N 0.000 description 1
- UOVKWFSUIIXOHN-ABNAAPPCSA-N (8r,9s,10r,13s,14s)-10,13-dimethyl-4-(phenylsulfanylmethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@@H]1[C@@H]([C@]2(CCC3=O)C)CC[C@]4([C@H]1CCC4=O)C)CC2=C3CSC1=CC=CC=C1 UOVKWFSUIIXOHN-ABNAAPPCSA-N 0.000 description 1
- ISMVMNHPEDSOTR-TXDMSJPOSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2)C[C@@H]1[C@]1(C)C2=C(C)C(=O)CC1 ISMVMNHPEDSOTR-TXDMSJPOSA-N 0.000 description 1
- NGONWFWOPQHNQH-KUVPCWQVSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-6-methylidene-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2=C)C[C@@H]1[C@]1(C)C2=C(C)C(=O)CC1 NGONWFWOPQHNQH-KUVPCWQVSA-N 0.000 description 1
- BVCKDXQMHVMAQI-KUVPCWQVSA-N (8r,9s,10r,13s,14s)-4,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C([C@]1(C)C(=O)CC[C@H]1[C@@H]1CC2=C)C[C@@H]1[C@]1(C)C2=C(C)C(=O)C=C1 BVCKDXQMHVMAQI-KUVPCWQVSA-N 0.000 description 1
- NZSZWFHPDWZPMV-YRJWVXGYSA-N (8r,9s,10s,13s,14s)-1,10,13-trimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C NZSZWFHPDWZPMV-YRJWVXGYSA-N 0.000 description 1
- MSWDXKNJTDCILH-FHHGAAIESA-N (8r,9s,10s,13s,14s)-1-ethyl-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione Chemical compound C1C[C@@H]2[C@@]3(C)C(CC)=CC(=O)C=C3C(=C)C[C@H]2[C@@H]2CCC(=O)[C@]21C MSWDXKNJTDCILH-FHHGAAIESA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001649081 Dina Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710162501 Ovarian aromatase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- UYJXRRSPUVSSMN-UHFFFAOYSA-P ammonium sulfide Chemical compound [NH4+].[NH4+].[S-2] UYJXRRSPUVSSMN-UHFFFAOYSA-P 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-O azanium;hydron;hydroxide Chemical compound [NH4+].O VHUUQVKOLVNVRT-UHFFFAOYSA-O 0.000 description 1
- -1 bromine compound Chemical class 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- OPHUWKNKFYBPDR-UHFFFAOYSA-N copper lithium Chemical compound [Li].[Cu] OPHUWKNKFYBPDR-UHFFFAOYSA-N 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB858517360A GB8517360D0 (en) | 1985-07-09 | 1985-07-09 | Substituted androsta-1,4-diene-3,17-diones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1442077A3 true SU1442077A3 (ru) | 1988-11-30 |
Family
ID=10582036
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU864027793A SU1442077A3 (ru) | 1985-07-09 | 1986-07-08 | Способ получени замещенных андроста-1,4-диен-3,17-дионов |
| SU874203488A SU1501923A3 (ru) | 1985-07-09 | 1987-10-15 | Способ получени замещенных андроста - 1,4-диен-3,17-дионов |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU874203488A SU1501923A3 (ru) | 1985-07-09 | 1987-10-15 | Способ получени замещенных андроста - 1,4-диен-3,17-дионов |
Country Status (38)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
| GB8617107D0 (en) * | 1986-07-14 | 1986-08-20 | Erba Farmitalia | 6-/7-methylenandrosta-1 4-diene-3 17-dione derivatives |
| GB8622330D0 (en) * | 1986-09-17 | 1986-10-22 | Erba Farmitalia | 4-substituted 6-alkylidenandrostene-3,17-dione derivatives |
| DE3715869A1 (de) * | 1987-05-07 | 1988-11-17 | Schering Ag | Verfahren zur herstellung von 1-methyl-androsta-1,4-dien-3,17-dion und die neuen zwischenprodukte fuer dieses verfahren |
| GB8721384D0 (en) * | 1987-09-11 | 1987-10-21 | Erba Farmitalia | 17-substituted andro-sta-1 4-dien-3-one derivatives |
| GB8721383D0 (en) * | 1987-09-11 | 1987-10-21 | Erba Farmitalia | Preparation of methylene derivatives |
| GB8801697D0 (en) * | 1988-01-26 | 1988-02-24 | Erba Farmitalia | Improvements in synthesis of 6-methylene derivatives of androsta-1 4-diene-3 17-dione |
| WO1992017489A1 (fr) * | 1991-03-28 | 1992-10-15 | Teikoku Hormone Mfg. Co., Ltd. | Nouveau derive oxa- ou azasteroide |
| CH683151A5 (de) * | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
| GB9201224D0 (en) * | 1992-01-21 | 1992-03-11 | Erba Carlo Spa | Difluoromethylenandrostenone derivatives and process for their preparation |
| HU221191B1 (en) * | 1992-09-30 | 2002-08-28 | Teikoku Hormone Mfg Co Ltd | 7-substituted oxasteroid compounds, process for their preparation and pharmaceutical compositions containing the same |
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| GB9313420D0 (en) * | 1993-06-29 | 1993-08-11 | Erba Carlo Spa | Fluorinated 6-methylenandrosta-1,4-dien-3-one-derivatives and process for their preparations |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| AU5873300A (en) * | 1999-07-07 | 2001-01-30 | Pharmacia & Upjohn Company | Process to prepare exemestane |
| GB9930839D0 (en) * | 1999-12-30 | 2000-02-16 | Pharmacia & Upjohn Spa | Process for treating gynecomastia |
| GB0005257D0 (en) * | 2000-03-03 | 2000-04-26 | Pharmacia & Upjohn Spa | Breast cancer hormonal therapy |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| GB0017635D0 (en) * | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
| US20030158168A1 (en) * | 2000-08-09 | 2003-08-21 | Giorgio Massimini | Composition for combined use of aromatase inhibitors |
| KR20030043955A (ko) * | 2000-09-08 | 2003-06-02 | 파마시아 이탈리아 에스.피.에이. | 화학적 예방제로서 엑스메스탄 |
| ATE337787T1 (de) * | 2001-01-26 | 2006-09-15 | Pfizer Italia Srl | Exemestan zur behandlung von hormonabhängigen störungen |
| US20040082557A1 (en) * | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
| LT3351246T (lt) | 2001-02-19 | 2019-07-10 | Novartis Pharma Ag | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
| PL392652A1 (pl) | 2001-05-16 | 2010-12-06 | Novartis Ag | Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację |
| GB0120147D0 (en) * | 2001-08-17 | 2001-10-10 | Metris Therapeutics Ltd | Treatment method |
| US20040043938A1 (en) * | 2001-11-06 | 2004-03-04 | Dinesh Purandare | Combination therapy for estrogen-dependent disorders |
| GB0128510D0 (en) * | 2001-11-28 | 2002-01-23 | Novartis Ag | Organic compounds |
| ES2316758T3 (es) | 2002-05-16 | 2009-04-16 | Novartis Ag | Uso de aglutinantes del receptor edg en el cancer. |
| CN1304413C (zh) * | 2002-10-24 | 2007-03-14 | 上海华拓医药科技发展有限公司 | 一种抗癌药物依西美坦制备方法 |
| CN1317293C (zh) * | 2002-10-24 | 2007-05-23 | 南京长澳医药科技有限公司 | 一种依西美坦的合成工艺 |
| US20040186160A1 (en) * | 2002-12-13 | 2004-09-23 | Sugen, Inc. | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors |
| WO2005027916A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and aromatase inhibitors |
| US20050101579A1 (en) * | 2003-11-06 | 2005-05-12 | Shippen Eugene R. | Endometriosis treatment protocol |
| ES2382609T3 (es) * | 2004-01-16 | 2012-06-11 | Cedarburg Pharmaceuticals, Inc. | Exemestano y sus productos intermedios y métodos de preparación de los mismos |
| US7435757B2 (en) * | 2004-07-02 | 2008-10-14 | Schering Ag | 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1 |
| US10174070B2 (en) | 2005-09-30 | 2019-01-08 | Endece Llc | 6-substituted estradiol derivatives and methods of use |
| US8168621B2 (en) | 2005-09-30 | 2012-05-01 | Endece, Llc | 6-substituted estradiol derivatives and methods of use |
| US20080119447A1 (en) * | 2005-09-30 | 2008-05-22 | James Yarger | 6-alkoxyalkyl estradiol derivatives and methods of use |
| CA2624269C (en) | 2005-09-30 | 2016-03-22 | Endece, Llc | Exemestane compounds, compositions and related uses thereof |
| DE102006008074B4 (de) * | 2006-02-22 | 2013-08-14 | RUHR-UNIVERSITäT BOCHUM | Behandlung von Krebs mit Geruchsrezeptor-Liganden |
| WO2007128820A1 (en) | 2006-05-09 | 2007-11-15 | Novartis Ag | Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| WO2008033466A2 (en) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions and methods for treatment of viral diseases |
| US20080275259A1 (en) * | 2007-05-04 | 2008-11-06 | Scinopharm Taiwan, Ltd | Process for preparing aromatase inhibitors |
| CN102940619A (zh) | 2007-10-16 | 2013-02-27 | 利普生物药剂公司 | 用于治疗代谢综合征的珠氯米芬 |
| EP2070943A1 (en) * | 2007-12-14 | 2009-06-17 | Crystal Pharma, S.A. | Process for obtaining 6-Alkylidenandrost-1,4-diene-3one |
| CN101468023B (zh) * | 2007-12-26 | 2011-02-02 | 上海复星医药（集团）股份有限公司 | 依西美坦片及其制备工艺 |
| ES2461092T3 (es) * | 2008-01-21 | 2014-05-16 | Cadila Healthcare Limited | Procedimiento para preparar el inhibidor de aromatasa Exemestano |
| GB0813628D0 (en) * | 2008-07-25 | 2008-09-03 | Arrow Int Ltd | Stable coated anti-cancer agent |
| WO2010076811A2 (en) * | 2008-12-30 | 2010-07-08 | Ind-Swift Laboratories Limited | Process for the preparation of exemestane |
| WO2010127297A1 (en) | 2009-05-01 | 2010-11-04 | Parviz Gharagozloo | Treating male infertility secondary to sperm oxidative stress |
| RU2425052C1 (ru) * | 2010-03-04 | 2011-07-27 | Татьяна Степановна Савинова | Способ получения 6-метиленандрост-4-ен-3,17-диона из андрост-4-ен-3,17-диона, способ получения 6-метиленандроста-1,4-диен-3,17-диона (эксеместана) с использованием полученного 6-метиленандрост-4-ен-3,17-диона |
| DE102010003494A1 (de) * | 2010-03-31 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Parenterales Abgabesystem, das Aromatasehemmer und Gestagene freisetzt, für die Behandlung von Endometriose |
| US8969327B2 (en) | 2010-04-08 | 2015-03-03 | Emory University | Substituted androst-4-ene diones |
| EP2558098A2 (en) | 2010-04-16 | 2013-02-20 | Novartis AG | Treatment of endocrine resistant breast cancer |
| ES2605960T3 (es) | 2010-09-14 | 2017-03-17 | Endece, Llc | Derivados de desmetil-estradiol 6-sustituido como agonistas del RE-beta |
| MX2014009322A (es) | 2012-02-29 | 2014-11-10 | Repros Therapeutics Inc | Terapia de combinacion para el tratamiento de la deficiencia androgenica. |
| US20170165246A1 (en) | 2014-02-11 | 2017-06-15 | Novartis Ag | Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer |
| JP7048505B2 (ja) | 2015-11-10 | 2022-04-05 | パラクリン セラピューティクス エービー | Ｐｄｇｆ－ｃｃ阻害剤および抗エストロゲン剤によるｅｒ陰性乳癌の処置 |
| CN112409432B (zh) * | 2020-11-16 | 2023-07-07 | 陕西理工大学 | 一种依西美坦的合成方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB929985A (enExample) * | ||||
| US2744120A (en) * | 1953-01-14 | 1956-05-01 | Olin Mathieson | 1-dehydrotestololactone |
| US3112305A (en) * | 1960-11-07 | 1963-11-26 | British Drug Houses Ltd | 6-methylene-3-oxo-delta4-steroids and process for their preparation |
| GB1042291A (en) * | 1961-11-08 | 1966-09-14 | Organon Labor Ltd | í¸-6ª‡-amino steroids and the preparation thereof |
| DK120154B (da) * | 1968-02-29 | 1971-04-19 | Schering Ag | Fremgangsmåde til fremstilling af N-substituerede 4-amino-3-oxosteroid-4,6-diener af androstan- eller pregnanrækken eller deres ammoniumsalte. |
| BE759143A (fr) * | 1969-11-19 | 1971-05-19 | Upjohn Co | Procede de preparation d'un nouveau compose steroide |
| US4235893A (en) * | 1978-05-08 | 1980-11-25 | Brodie Angela M | Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis |
| DE3004508C2 (de) * | 1980-02-05 | 1981-12-10 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Verfahren zur Herstellung von 6-Methylensteroiden |
| DE3322285A1 (de) * | 1983-06-18 | 1984-12-20 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1-alkyl-androsta-1,4-dien-3,17-dione, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4512986A (en) * | 1983-07-26 | 1985-04-23 | Research Triangle Institute | Progrestationally active steroids |
| GB8517360D0 (en) * | 1985-07-09 | 1985-08-14 | Erba Farmitalia | Substituted androsta-1,4-diene-3,17-diones |
-
1985
- 1985-07-09 GB GB858517360A patent/GB8517360D0/en active Pending
-
1986
- 1986-06-24 ES ES556550A patent/ES8801304A1/es not_active Expired
- 1986-07-02 IT IT21004/86A patent/IT1196436B/it active Protection Beyond IP Right Term
- 1986-07-04 HU HU862820A patent/HU194274B/hu unknown
- 1986-07-04 IL IL79336A patent/IL79336A/xx not_active IP Right Cessation
- 1986-07-04 AT AT0181986A patent/AT395157B/de not_active IP Right Cessation
- 1986-07-04 CH CH2706/86A patent/CH668599A5/de not_active IP Right Cessation
- 1986-07-07 AU AU59799/86A patent/AU578840B2/en not_active Expired
- 1986-07-07 US US06/882,364 patent/US4808616A/en not_active Expired - Lifetime
- 1986-07-07 NZ NZ216763A patent/NZ216763A/en unknown
- 1986-07-07 IE IE182186A patent/IE58949B1/en not_active IP Right Cessation
- 1986-07-07 FI FI862871A patent/FI83424C/fi not_active IP Right Cessation
- 1986-07-08 GR GR861780A patent/GR861780B/el unknown
- 1986-07-08 KR KR1019860005489A patent/KR950003614B1/ko not_active Expired - Lifetime
- 1986-07-08 DE DE2001199030 patent/DE10199030I1/de active Pending
- 1986-07-08 UA UA4027793A patent/UA6046A1/uk unknown
- 1986-07-08 YU YU1201/86A patent/YU44585B/xx unknown
- 1986-07-08 PT PT82944A patent/PT82944B/pt unknown
- 1986-07-08 GB GB08616585A patent/GB2177700B/en not_active Expired
- 1986-07-08 SU SU864027793A patent/SU1442077A3/ru active
- 1986-07-08 FR FR8609922A patent/FR2584725B1/fr not_active Expired
- 1986-07-08 ZA ZA865079A patent/ZA865079B/xx unknown
- 1986-07-08 CN CN86104664A patent/CN86104664B/zh not_active Expired
- 1986-07-08 SE SE8603046A patent/SE468988B/sv not_active IP Right Cessation
- 1986-07-08 NO NO862753A patent/NO165547C/no not_active IP Right Cessation
- 1986-07-08 NL NL8601785A patent/NL193616C/nl not_active IP Right Cessation
- 1986-07-08 CA CA000513267A patent/CA1277656C/en not_active Expired - Lifetime
- 1986-07-08 JP JP61158891A patent/JPS6212797A/ja active Granted
- 1986-07-08 BE BE0/216890A patent/BE905067A/fr not_active IP Right Cessation
- 1986-07-08 DK DK324386A patent/DK163520C/da not_active IP Right Cessation
- 1986-07-08 PH PH33989A patent/PH21785A/en unknown
- 1986-07-09 CS CS873216A patent/CS258498B2/cs not_active IP Right Cessation
- 1986-07-09 CS CS865214A patent/CS257794B2/cs not_active IP Right Cessation
-
1987
- 1987-03-26 ES ES557466A patent/ES8802429A1/es not_active Expired
- 1987-06-05 YU YU1036/87A patent/YU44628B/xx unknown
- 1987-10-15 SU SU874203488A patent/SU1501923A3/ru active
-
1988
- 1988-07-26 US US07/225,674 patent/US4904650A/en not_active Expired - Lifetime
- 1988-12-30 MY MYPI88001585A patent/MY102294A/en unknown
-
1990
- 1990-10-03 SG SG804/90A patent/SG80490G/en unknown
- 1990-11-15 HK HK941/90A patent/HK94190A/xx not_active IP Right Cessation
-
1991
- 1991-12-30 CZ CS914135A patent/CZ413591A3/cs unknown
- 1991-12-30 SK SK4135-91A patent/SK413591A3/sk unknown
-
1994
- 1994-02-22 BG BG098516A patent/BG61370B2/bg unknown
-
1997
- 1997-04-08 BR BR1100240-9A patent/BR1100240A/pt active IP Right Grant
-
2000
- 2000-09-14 NL NL300017C patent/NL300017I2/nl unknown
- 2000-10-05 NO NO2000009C patent/NO2000009I1/no unknown
Non-Patent Citations (1)
| Title |
|---|
| Патент US № 4322416, кл. 424-242, 1975. Патент GB Р 929985, кл. 2 (ЗС), 1968. Рингрльд Г.Дж. и др. Хими и про- мьшшениость, 1962, с, 211. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1442077A3 (ru) | Способ получени замещенных андроста-1,4-диен-3,17-дионов | |
| DE3871965T2 (de) | Steroid-5-alpha-reduktase-inhibitoren. | |
| DK163129B (da) | Analogifremgangsmaade til fremstilling af 10-(1,2-propadienyl)-steroider | |
| SU1549485A3 (ru) | Способ получени производных 6-метиленандроста-1,4-диен-3,17-диона | |
| JP2677626B2 (ja) | １７−置換アンドロスタ−１，４−ジエン−３−オン誘導体 | |
| DK171968B1 (da) | 5-androsten-17-on-forbindelser samt terapeutisk præparat, der indeholder en sådan forbindelse | |
| US5137882A (en) | Steroidal 3-acetic acid derivatives as 5-alpha-reductase inhibitors | |
| JPS635096A (ja) | 新規なアンドロスト−４−エン−３，１７−ジオンおよびその製造方法 | |
| JPH07506120A (ja) | フッ素化４−アミノアンドロスタジエノン誘導体及びその製造方法 | |
| EP0289451B1 (de) | 3-Methylen-4-androsten-17-one, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate | |
| SU1540656A3 (ru) | Способ получени стероидов или их фармацевтически приемлемых солей | |
| US4578475A (en) | Novel D-homosteroids | |
| Popper et al. | Antiandrogenic and progestational activity of some 17-oxygenated 15-dehydro steroids | |
| US3094521A (en) | Alkanoylthio and pyrazolo androstane derivatives | |
| DE3622841C2 (de) | Substituierte Androsta-1,4-dien-3,17-dione und Verfahren zu deren Herstellung | |
| DE3719913A1 (de) | Methylenderivate und androst-4-en-3,17-dionen und verfahren zu deren herstellung | |
| JPH08500609A (ja) | フッ素化６−メチレンアンドロスタ−１，４−ジエン−３−オン誘導体及び該誘導体の製造方法 | |
| Weier et al. | Synthesis and antimineralocorticoid activities of some 6-substituted 7. alpha.-carboalkoxy steroidal spirolactones | |
| EP0608404A1 (en) | ANDROST-4-EN (4,5-B) -PYRROL DERIVATIVES AND A METHOD FOR THE PRODUCTION THEREOF. | |
| JPH0132237B2 (enExample) | ||
| JPH07502759A (ja) | ６，７α−ジフルオロメチレンアンドロスタ−１，４−ジエン−３−オン誘導体及び該誘導体の製造方法 | |
| JP2005504786A (ja) | メチレンー４−アザステロイド | |
| GB2284605A (en) | 6-or 7-substituted 4-aminoandrostadienone derivatives | |
| SI8611201A8 (sl) | Postopek za pridobivanje substituiranih androsta -1,4-dien-3,17-dionov |